Column Group IV GP, LP
CIK: 0001796356
Column Group IV GP, LP's purchase track record
Column Group IV GP, LP has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/3/2026 | EIKN | $1.03M | pending | pending | — |
| 2/6/2026 | EIKN | $38.12M | -31.3% | -35.9% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| EIKN | ▲ Buy | Open Market | 89,200 | $1.0M | 9/3/2026 | View on chart |
| EIKN | ▼ Sell | Other | 1,296,629 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 1,403,568 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 110,928 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 44,249 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 47,898 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 3,785 | — | 2/6/2026 | View on chart |
| EIKN | ▼ Sell | Other | 688,283 | — | 2/6/2026 | View on chart |
| EIKN | ▲ Buy | Open Market | 1,437,323 | $25.9M | 2/6/2026 | View on chart |
| EIKN | ▲ Buy | Open Market | 49,556 | $892K | 2/6/2026 | View on chart |
| EIKN | ▲ Buy | Open Market | 630,881 | $11.4M | 2/6/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
EIKN sees institutional buying following NVIDIA and Merck moves
Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.
EIKN sees institutional buying following NVIDIA and Merck moves. Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.